Amgen Inc

NASDAQ:AMGNUnited States

Nov 14, 2024

Show headlines and story abstract

• AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024, from 4:00PM ET on Thursday Nov 14, 2024 by PR Newswire

  4:00PM ET on Thursday Nov 14, 2024 by PR Newswire
  Companies Mentioned: AMGN

  MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA(R) asthe First Potential Treatment tor IgG4-RD

  Phase 4 AGILE Data Support Shortening KRYSTEXXA(R) Infusion Time

  Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., Nov. 14-19, 2024. New data showcase reduction in disease activityby UPLIZNA(R) (inebilizumab-cdon) in Immunoglobulin G4-Related Disease (IgG4-RD) and support shorter infusion times for KRYSTEXXA(R)(pegloticase) co-administered with weekly oral methotrexate 15 mg.

• AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024, from 4:00PM ET on Thursday Nov 14, 2024 by Dow Jones

  4:00PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
  

• DJ 5 Healthcare Stocks to Buy in a Beaten-Up Sector -- Barrons.com, from 1:53PM ET on Thursday Nov 14, 2024 by Dow Jones

  1:53PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: LLY, PFE, XLV, AMGN, BIIB
  
  By Jacob Sonenshine
  
  It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.
  
  The Health Care Select Sector SPDR Fund, which owns shares of major U.S. health insurers, medical device makers, and drugmakers, has dropped about 7% since hitting a record high in mid-September. Investors have been selling healthcare stocks, buying up more economically-sensitive ones instead, as the Federal Reserve has cut interest rates and the market accounts for the positive economic consequences from Republicans winning the White House and both chambers of Congress.